New Partnership to Provide Bioanalytical and DMPK Services
Concept Life Sciences (“Concept”), the integrated drug discovery, development and analytical services company, and Alderley Analytical, the GLP/GCP compliant, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Under the terms of the agreement, Concept will gain access to Alderley Analytical’s significant expertise in bioanalysis, and Alderley Analytical will benefit from Concept’s deep understanding of synthetic, organic and medicinal chemistry, biology, toxicology, and analytical services. The combined offering will give clients of both companies, including biotech, pharma and agrochemicals companies, access to industry-leading assay development services for quantification of new molecules in a biological matrix, using the most sensitive instrumentation available.
Michael Fort, Executive Chairman, Concept Life Sciences, commented: “The team at Alderley Analytical has built an impressive reputation for delivery of the highest quality GLP/GCP bioanalytical services. Combining this offering with our Group’s expertise, including the recent additions of translational biology and large molecule research, brings benefits to the widest group of life sciences clients.”
This article has been republished from materials provided by Concept Life Sciences. Note: material may have been edited for length and content. For further information, please contact the cited source.
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Researchers Test Drug Transfer Using Placenta-On-A-ChipNews
Researchers have demonstrated the feasibility of their "organ-on-a-chip" platform in studying how drugs are transported across the human placental barrier.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018